Tocainide suppression of immune-complex-mediated dermal inflammation

Comparison with prostaglandin E1

Richard H White, Dick L. Robbins, Gary L. Henderson, Dallas M. Hyde

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Local anesthetic agents have been shown to alter a variety of polymorphonuclear leukocyte (PMN) functions and may be useful as anti-inflammatory agents. We compared the anti-inflammatory effects of therapeutic doses of the recently released local anesthetic-antiarrythmic drug tocainide to pharmacologic doses of prostaglandin E1 (PGE1) on immune-complex-mediated dermal inflammation in female Sprague-Dawley rats. Intense dermal inflammation was produced using a classic reverse passive Arthus reaction, and the inhibition of PMN accumulation in the subdermis was quantitated in biopsy samples taken 2.5 hr after the reaction was initiated and the drug was given. Using a light microscope with a counting grid, biopsy sections were randomly sampled in a blinded fashion and an inflammation index equal to the ratio of PMNs to fibroblasts was determined for each animal. The mean inflammation index in 10 animals given 25 mg of tocainide (mean serum level = 14.6 μg/ml) was 9.3 ± 1.2 (±SEM), which was significantly less than the index of 17.7 ± 2.5 in 10 control animals (P < 0.025). Similarly, the five animals that received either 500 or 250 μg of PGE1 had a significantly reduced index, with the effect of 250 μg PGE1 comparable to the effect of the tocainide. These findings suggest that therapeutic levels of tocainide reduce the accumulation of PMNs in immune-complex-mediated dermal inflammation; thus, local anesthetic agents may be useful in the treatment of certain inflammatory disorders.

Original languageEnglish (US)
Pages (from-to)452-463
Number of pages12
JournalClinical Immunology and Immunopathology
Volume39
Issue number3
DOIs
StatePublished - 1986

Fingerprint

Tocainide
Alprostadil
Antigen-Antibody Complex
Inflammation
Skin
Local Anesthetics
Anesthetics
Neutrophils
Anti-Inflammatory Agents
Arthus Reaction
Biopsy
Therapeutic Uses
Sprague Dawley Rats
Fibroblasts
Light
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Tocainide suppression of immune-complex-mediated dermal inflammation : Comparison with prostaglandin E1. / White, Richard H; Robbins, Dick L.; Henderson, Gary L.; Hyde, Dallas M.

In: Clinical Immunology and Immunopathology, Vol. 39, No. 3, 1986, p. 452-463.

Research output: Contribution to journalArticle

@article{a535116825eb46fe9234aa78d4b84197,
title = "Tocainide suppression of immune-complex-mediated dermal inflammation: Comparison with prostaglandin E1",
abstract = "Local anesthetic agents have been shown to alter a variety of polymorphonuclear leukocyte (PMN) functions and may be useful as anti-inflammatory agents. We compared the anti-inflammatory effects of therapeutic doses of the recently released local anesthetic-antiarrythmic drug tocainide to pharmacologic doses of prostaglandin E1 (PGE1) on immune-complex-mediated dermal inflammation in female Sprague-Dawley rats. Intense dermal inflammation was produced using a classic reverse passive Arthus reaction, and the inhibition of PMN accumulation in the subdermis was quantitated in biopsy samples taken 2.5 hr after the reaction was initiated and the drug was given. Using a light microscope with a counting grid, biopsy sections were randomly sampled in a blinded fashion and an inflammation index equal to the ratio of PMNs to fibroblasts was determined for each animal. The mean inflammation index in 10 animals given 25 mg of tocainide (mean serum level = 14.6 μg/ml) was 9.3 ± 1.2 (±SEM), which was significantly less than the index of 17.7 ± 2.5 in 10 control animals (P < 0.025). Similarly, the five animals that received either 500 or 250 μg of PGE1 had a significantly reduced index, with the effect of 250 μg PGE1 comparable to the effect of the tocainide. These findings suggest that therapeutic levels of tocainide reduce the accumulation of PMNs in immune-complex-mediated dermal inflammation; thus, local anesthetic agents may be useful in the treatment of certain inflammatory disorders.",
author = "White, {Richard H} and Robbins, {Dick L.} and Henderson, {Gary L.} and Hyde, {Dallas M.}",
year = "1986",
doi = "10.1016/0090-1229(86)90173-X",
language = "English (US)",
volume = "39",
pages = "452--463",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Tocainide suppression of immune-complex-mediated dermal inflammation

T2 - Comparison with prostaglandin E1

AU - White, Richard H

AU - Robbins, Dick L.

AU - Henderson, Gary L.

AU - Hyde, Dallas M.

PY - 1986

Y1 - 1986

N2 - Local anesthetic agents have been shown to alter a variety of polymorphonuclear leukocyte (PMN) functions and may be useful as anti-inflammatory agents. We compared the anti-inflammatory effects of therapeutic doses of the recently released local anesthetic-antiarrythmic drug tocainide to pharmacologic doses of prostaglandin E1 (PGE1) on immune-complex-mediated dermal inflammation in female Sprague-Dawley rats. Intense dermal inflammation was produced using a classic reverse passive Arthus reaction, and the inhibition of PMN accumulation in the subdermis was quantitated in biopsy samples taken 2.5 hr after the reaction was initiated and the drug was given. Using a light microscope with a counting grid, biopsy sections were randomly sampled in a blinded fashion and an inflammation index equal to the ratio of PMNs to fibroblasts was determined for each animal. The mean inflammation index in 10 animals given 25 mg of tocainide (mean serum level = 14.6 μg/ml) was 9.3 ± 1.2 (±SEM), which was significantly less than the index of 17.7 ± 2.5 in 10 control animals (P < 0.025). Similarly, the five animals that received either 500 or 250 μg of PGE1 had a significantly reduced index, with the effect of 250 μg PGE1 comparable to the effect of the tocainide. These findings suggest that therapeutic levels of tocainide reduce the accumulation of PMNs in immune-complex-mediated dermal inflammation; thus, local anesthetic agents may be useful in the treatment of certain inflammatory disorders.

AB - Local anesthetic agents have been shown to alter a variety of polymorphonuclear leukocyte (PMN) functions and may be useful as anti-inflammatory agents. We compared the anti-inflammatory effects of therapeutic doses of the recently released local anesthetic-antiarrythmic drug tocainide to pharmacologic doses of prostaglandin E1 (PGE1) on immune-complex-mediated dermal inflammation in female Sprague-Dawley rats. Intense dermal inflammation was produced using a classic reverse passive Arthus reaction, and the inhibition of PMN accumulation in the subdermis was quantitated in biopsy samples taken 2.5 hr after the reaction was initiated and the drug was given. Using a light microscope with a counting grid, biopsy sections were randomly sampled in a blinded fashion and an inflammation index equal to the ratio of PMNs to fibroblasts was determined for each animal. The mean inflammation index in 10 animals given 25 mg of tocainide (mean serum level = 14.6 μg/ml) was 9.3 ± 1.2 (±SEM), which was significantly less than the index of 17.7 ± 2.5 in 10 control animals (P < 0.025). Similarly, the five animals that received either 500 or 250 μg of PGE1 had a significantly reduced index, with the effect of 250 μg PGE1 comparable to the effect of the tocainide. These findings suggest that therapeutic levels of tocainide reduce the accumulation of PMNs in immune-complex-mediated dermal inflammation; thus, local anesthetic agents may be useful in the treatment of certain inflammatory disorders.

UR - http://www.scopus.com/inward/record.url?scp=0022479980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022479980&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(86)90173-X

DO - 10.1016/0090-1229(86)90173-X

M3 - Article

VL - 39

SP - 452

EP - 463

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -